Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Section Content Menu
Skip to Common Links
U.S. Food & Drug Administration
A to Z Index
Follow FDA
FDA Voice Blog
Enter Search terms
Most Popular Searches
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Drugs
Home
Drugs
Drug Safety and Availability
Postmarket Drug Safety Information for Patients and Providers
Section Contents Menu
Drug Safety and Availability
Postmarket Drug Safety Information for Patients and Providers
Index to Drug-Specific Information
Approved Risk Evaluation and Mitigation Strategies (REMS)
Drug Safety Information for Healthcare Professionals
-
Regranex (becaplermin) Information
-
Related Information
Communication about an Ongoing Safety Review of Regranex (becaplermin)
3/27/2008
Update of Safety Review: Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Regranex (becaplermin)
6/6/2008
-
Contact FDA
1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem
MedWatch Online
Regular Mail:
Use postage-paid
FDA Form 3500
Mail to:
MedWatch 5600 Fishers Lane
Rockville, MD 20857
-
-